8-K: Rafael Holdings' Niemann-Pick Disease Drug Advances to Full Phase 3 Study After Positive Interim Review

Rafael Holdings, Inc. announced that its pivotal Phase 3 TransportNPC study for Niemann-Pick Disease Type C1 (NPC1) will continue to its full 96-week duration following a positive independent Data Monitoring Committee review of interim safety and efficacy data.

Summary

• Rafael Holdings, Inc. announced that its subsidiary Cyclo Therapeutics' 96-week pivotal Phase 3 TransportNPC study evaluating intravenous (IV) Trappsol Cyclo for the potential treatment of Niemann-Pick Disease Type C1 (NPC1) will continue.
• This decision is based on the independent Data Monitoring Committee (DMC) review of safety and efficacy data at the prespecified 48-week interim analysis.
• The investigational candidate, Trappsol Cyclo (hydroxypropyl-beta-cyclodextrin), has been found to be well-tolerated with a safety profile consistent with previously completed Phase 1 and 2 studies and an ongoing Phase 1 open-label extension study.
• The Food and Drug Administration (FDA) has accepted the statistical analysis plan for the TransportNPC study.
• Niemann-Pick Disease Type C1 (NPC1) is a rare, fatal, and progressive genetic disease affecting approximately 1 in 100,000 live births globally, characterized by the inability of cells to transport and process cholesterol, leading to organ damage.
• The TransportNPC study enrolled 94 patients across over 25 sites in 13 countries.
• Primary endpoints for the study include the mean change in the 4-domain NPC Clinical Severity Scale (4D-NPC-CSS) score in the United States and the 5-domain NPC Clinical Severity Scale (5D-NPC-CSS) score in Europe.
• A Phase 3 open-label sub-study is being conducted in NPC1 patients from birth to 3 years of age outside the United States, with ten patients recruited and continuing.
• Rafael Holdings recently enhanced its financial position with the closing of a $25 million rights offering earlier in June 2025.

Sentiment

Score: 8

Explanation: The continuation of a pivotal Phase 3 study after a positive interim analysis is a significant positive milestone for a biotechnology company, indicating the drug is progressing as hoped. The FDA's acceptance of the statistical analysis plan and the recent capital raise further strengthen the positive outlook.

Positives

• The pivotal Phase 3 TransportNPC study for Trappsol Cyclo will continue to its full 96-week duration, indicating positive interim safety and efficacy data.
• The independent Data Monitoring Committee (DMC) recommended the continuation of the study after reviewing the 48-week interim analysis, signifying confidence in the drug's profile.
• Trappsol Cyclo has demonstrated a well-tolerated safety profile, consistent with previous clinical studies.
• The Food and Drug Administration (FDA) has accepted the statistical analysis plan for the TransportNPC study, which is a crucial regulatory validation.
• Rafael Holdings recently completed a $25 million rights offering, strengthening its financial position to support strategic objectives and ongoing clinical development.
• Trappsol Cyclo is designed to directly impact the root cause of NPC1 by mobilizing cholesterol and has shown to cross the blood-brain barrier, suggesting potential for systemic and neurological treatment.

Risks

• The press release contains forward-looking statements that involve known and unknown risks, uncertainties, and other important factors that may cause actual results to differ materially from expectations. These factors are disclosed under the caption "Risk Factors" in the company's Annual Report on Form 10-K for the year ended July 31, 2024, and other SEC filings.

Future Outlook

The company is committed to advancing Trappsol Cyclo through late-stage clinical development to support global regulatory and commercial readiness. The study will continue to its full 96-week duration to further evaluate the potential of Trappsol Cyclo as a systemic and neurological treatment option for NPC1. The potential clinical significance of Trappsol Cyclo's concentrations in the central nervous system will be evaluated based on the full results of the Phase 3 TransportNPC study.

Management Comments

• "NPC is a rare, fatal, and progressive genetic disease, and there is a need for safe and effective treatment that addresses its root cause." Howard S. Jonas, CEO of Rafael Holdings.
• "The recommendation made by the independent DMC to continue the study to 96 weeks, boosts our determination to the continued clinical evaluation of the potential of TrappsolCyclo as a systemic and neurological treatment option for people living with NPC1." Howard S. Jonas, CEO of Rafael Holdings.
• "We recently enhanced our financial position with the closing of a $25 million rights offering earlier this month which will support our strategic objectives." Howard S. Jonas, CEO of Rafael Holdings.
• "It is a privilege to lead and continue the TransportNPC study, the most comprehensive, controlled pivotal study of an investigational therapy for NPC ever conducted in terms of patient size, global footprint, duration, and clinical outcomes." N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics.
• "We are grateful to the study participants, their families, investigators, and clinical trial sites who are dedicated to this important research." N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics.

Industry Context

Niemann-Pick Disease Type C1 (NPC1) is a rare, fatal, and progressive genetic disease affecting approximately 1 in 100,000 live births globally, highlighting a significant unmet medical need for safe and effective treatments that address its root cause.

Comparison to Industry Standards

• The TransportNPC study is described by management as "the most comprehensive, controlled pivotal study of an investigational therapy for NPC ever conducted in terms of patient size, global footprint, duration, and clinical outcomes."

Stakeholder Impact

• Shareholders: Positive impact due to the advancement of the lead clinical candidate and successful capital raise, potentially increasing company value.
• Patients and Families (NPC1): Positive impact as the study continues towards potentially providing a new, effective treatment option for a rare and fatal genetic disease.
• Employees: Positive impact due to continued progress in clinical development and enhanced financial stability.
• Investigators and Clinical Trial Sites: Continued engagement and funding for important research.

Next Steps

• Continuation of the Phase 3 TransportNPC study to its full 96-week duration.
• Evaluation of the potential clinical significance of Trappsol Cyclo's concentrations in the central nervous system based on the full study results.
• Advancing Trappsol Cyclo through late-stage clinical development to support global regulatory and commercial readiness.
• Continued recruitment and study of patients in the Phase 3 open-label sub-study for NPC1 patients from birth to 3 years of age.

Key Dates

Recommendation

Keywords

Niemann-Pick Disease Type C1, NPC1, Trappsol Cyclo, hydroxypropyl-beta-cyclodextrin, Phase 3 clinical trial, TransportNPC study, rare genetic disease, orphan drug, clinical development, biotechnology, Rafael Holdings, Cyclo Therapeutics, FDA, Data Monitoring Committee, clinical trial results, drug development, rare disease treatment